Clinical Trials Directory

Trials / Unknown

UnknownNCT03298191

Tocolysis in Prevention of Preterm Labor

Comparative Study on Tocolysis in Prevention of Preterm Labour

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
300 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
Female
Age
17 Years – 40 Years
Healthy volunteers
Not accepted

Summary

Preterm birth is defined as birth before 37 completed weeks of gestation .it occurs in 11.1%of birth globally affecting an estimated 14.9 million babies every year . It is generally accepted that approximately 65%-70%of preterm births are spontaneous,40%-45% of them due to spontaneous preterm labor and 25%-30%following preterm rupture of membranes.preterm birth represents the single largest cause of morbidity and mortality for newborn and is estimated for 29%of deaths in the first four weeks of life and also is estimated for of major cause of morbidity for pregnant women . Tocolytic agents include a wide range of drugs that can slow or suppress uterine contractions . Tocolytic are considered advantages in spontaneous preterm labor to : (a) allow time for the fetus to mature ,potentially avoiding deleterious effects of pre-maturity . (b)allow time for antenatal corticosteroids to be administered and have clinical effect. (c) allow time for intrauterine transfer to higher-care center where neonatal intensive care facilities are available . the ideal Tocolytic agent should be effective , easy to administer , without significant material ,fetal or neonatal side effects and permit time for antenatal corticosteroids to be administered and take effect . a variety of Tocolytic treatments have been used to inhibit uterine activity in women in spontaneous preterm labor , including betamimetics , calcium channel blockers , magnesium sulfate , prostaglandin inhibitors and oxytocin receptor antagonists however there is considerable global variation in types , doses and regimens of tocolytic agents uses to manage preterm labor . A comparison study between Ritodrine, magnesium sulfate and Nifedipine in terms of effect and morbidity will be conducted.

Conditions

Interventions

TypeNameDescription
DRUGMagnesium SulfateThose women will be given Magnesium Sulfate for tocolysis
DRUGRitodrineThose women will be given Ritodrine for tocolysis
DRUGCalcium Channel BlockersThose women will be given Calcium Channel Blockers for tocolysis

Timeline

Start date
2017-10-25
Primary completion
2018-04-25
Completion
2018-05-25
First posted
2017-10-02
Last updated
2017-10-02

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03298191. Inclusion in this directory is not an endorsement.